Published in Cell on May 03, 2002
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
The essence of senescence. Genes Dev (2010) 8.21
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Four faces of cellular senescence. J Cell Biol (2011) 6.86
Senescence in tumours: evidence from mice and humans. Nat Rev Cancer (2010) 6.34
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
Aging, cellular senescence, and cancer. Annu Rev Physiol (2012) 5.08
Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol (2003) 4.05
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A (2007) 3.37
p53 and E2f: partners in life and death. Nat Rev Cancer (2009) 3.06
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat Cell Biol (2015) 2.85
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76
What has senescence got to do with cancer? Cancer Cell (2005) 2.55
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Therapy-induced senescence in cancer. J Natl Cancer Inst (2010) 2.45
Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol (2011) 2.42
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci U S A (2007) 2.39
When cells get stressed: an integrative view of cellular senescence. J Clin Invest (2004) 2.37
Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. Cold Spring Harb Symp Quant Biol (2005) 2.18
Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol (2009) 2.10
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc Natl Acad Sci U S A (2003) 2.07
The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A (2005) 2.01
20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer (2009) 2.00
Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol (2009) 1.99
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev (2010) 1.95
Cellular senescence and organismal aging. Mech Ageing Dev (2008) 1.92
Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. Genes Dev (2004) 1.84
The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas. PLoS Biol (2008) 1.79
Cell fusion induced by ERVWE1 or measles virus causes cellular senescence. Genes Dev (2013) 1.77
Cancer and radiation therapy: current advances and future directions. Int J Med Sci (2012) 1.76
Chemotherapeutic approaches for targeting cell death pathways. Oncologist (2006) 1.70
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations. Genes Dev (2011) 1.69
Cancer gene discovery in hepatocellular carcinoma. J Hepatol (2010) 1.68
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature (2013) 1.66
p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev (2010) 1.66
Role of the chromobox protein CBX7 in lymphomagenesis. Proc Natl Acad Sci U S A (2007) 1.65
Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol (2009) 1.64
Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol (2005) 1.61
Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res (2006) 1.60
c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-XL. Mol Cell Biol (2003) 1.59
Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol (2012) 1.56
CpG island hypermethylation frequently silences FILIP1L isoform 2 expression in prostate cancer. J Urol (2012) 1.56
BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. Cancer Discov (2016) 1.54
Targeting the RB-pathway in cancer therapy. Clin Cancer Res (2010) 1.54
MacroH2A1 and ATM Play Opposing Roles in Paracrine Senescence and the Senescence-Associated Secretory Phenotype. Mol Cell (2015) 1.53
Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev (2011) 1.52
Oncogene-induced cellular senescence elicits an anti-Warburg effect. Proteomics (2013) 1.50
Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev (2002) 1.49
Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov (2011) 1.46
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev (2007) 1.43
c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol (2002) 1.43
Continuous elimination of oxidized nucleotides is necessary to prevent rapid onset of cellular senescence. Proc Natl Acad Sci U S A (2008) 1.41
The p53-Bcl-2 connection. Cell Death Differ (2006) 1.39
A Quiescent Bcl11b High Stem Cell Population Is Required for Maintenance of the Mammary Gland. Cell Stem Cell (2016) 1.38
Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol Cell Biol (2008) 1.37
Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest (2008) 1.36
Functional genetic screens for enhancer elements in the human genome using CRISPR-Cas9. Nat Biotechnol (2016) 1.36
EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res (2011) 1.30
Normal human fibroblasts are resistant to RAS-induced senescence. Mol Cell Biol (2004) 1.30
Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc Natl Acad Sci U S A (2003) 1.30
p53-dependent senescence delays Emu-myc-induced B-cell lymphomagenesis. Oncogene (2009) 1.29
Hypoxia-inducible factor 1alpha determines gastric cancer chemosensitivity via modulation of p53 and NF-kappaB. PLoS One (2010) 1.27
ROC1/RBX1 E3 ubiquitin ligase silencing suppresses tumor cell growth via sequential induction of G2-M arrest, apoptosis, and senescence. Cancer Res (2009) 1.27
Targeting p53 for Novel Anticancer Therapy. Transl Oncol (2010) 1.26
Manganese superoxide dismutase induces p53-dependent senescence in colorectal cancer cells. Mol Cell Biol (2005) 1.26
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood (2012) 1.25
Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells. Dis Model Mech (2008) 1.25
Cellular senescence in cancer treatment: friend or foe? J Clin Invest (2004) 1.23
Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun (2016) 1.23
Mouse models of p53 functions. Cold Spring Harb Perspect Biol (2009) 1.23
Tumorigenicity of the miR-17-92 cluster distilled. Genes Dev (2010) 1.22
Senescence and apoptosis: dueling or complementary cell fates? EMBO Rep (2014) 1.21
Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A (2008) 1.20
Cold-inducible RNA-binding protein bypasses replicative senescence in primary cells through extracellular signal-regulated kinase 1 and 2 activation. Mol Cell Biol (2009) 1.20
Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood (2010) 1.19
The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle (2010) 1.17
Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol (2006) 1.16
Physiological and pathological consequences of cellular senescence. Cell Mol Life Sci (2014) 1.15
Granule exocytosis mediates immune surveillance of senescent cells. Oncogene (2012) 1.14
How to become immortal: let MEFs count the ways. Aging (Albany NY) (2010) 1.14
Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? J Clin Invest (2004) 1.14
p53 mediates senescence-like arrest induced by chronic replicational stress. Mol Cell Biol (2007) 1.11
Using mice to examine p53 functions in cancer, aging, and longevity. Cold Spring Harb Perspect Biol (2009) 1.10
Senescence induction; a possible cancer therapy. Mol Cancer (2009) 1.10
Cellular senescence requires CDK5 repression of Rac1 activity. Mol Cell Biol (2004) 1.10
A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep (2005) 1.09
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer (2010) 1.09
Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol (2010) 1.09
Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer (2010) 1.08
Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance. Mol Cell Biol (2012) 1.08
Gerosuppressant metformin: less is more. Aging (Albany NY) (2011) 1.08
ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer. Br J Cancer (2011) 1.08
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
Oncogene-induced senescence as an initial barrier in lymphoma development. Nature (2005) 9.16
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell (2006) 4.74
Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest (2004) 4.59
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
The microcosmos of cancer. Nature (2012) 4.50
Control of apoptosis by p53. Oncogene (2003) 4.46
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet (2006) 4.22
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol (2013) 3.77
Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest (2010) 3.74
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One (2009) 3.66
Apoptosis and melanoma chemoresistance. Oncogene (2003) 3.58
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (2011) 3.45
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system. Cancer Res (2006) 3.42
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol (2010) 3.33
Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A (2007) 3.26
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Nestin expression in hair follicle sheath progenitor cells. Proc Natl Acad Sci U S A (2003) 3.07
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
Stem cells: The promises and perils of p53. Nature (2009) 3.01
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Res (2009) 2.80
Multipotent nestin-positive, keratin-negative hair-follicle bulge stem cells can form neurons. Proc Natl Acad Sci U S A (2005) 2.78
Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci U S A (2005) 2.76
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Subcellular imaging in the live mouse. Nat Protoc (2006) 2.63
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res (2006) 2.51
Whole-body imaging with fluorescent proteins. Nat Protoc (2006) 2.51
mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A (2008) 2.50
In vivo internal tumor illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci U S A (2009) 2.46
Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer. Proc Natl Acad Sci U S A (2007) 2.46
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev (2012) 2.44
Fluorophore-conjugated anti-CEA antibody for the intraoperative imaging of pancreatic and colorectal cancer. J Gastrointest Surg (2008) 2.41
PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Senescence comes of age. Nat Med (2005) 2.39
Multipotent hair follicle stem cells promote repair of spinal cord injury and recovery of walking function. Cell Cycle (2008) 2.39
Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc (2006) 2.38
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res (2005) 2.37
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem (2008) 2.35
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of Salmonella typhimurium. Cell Cycle (2009) 2.28
Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation. World J Surg (2008) 2.27